InvestorWire NewsRoom

Articles

Articles Category: Biotechnology
Monday May 16, 2022 - 10:30 am

Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’

Aditxt is commercializing new innovations with focus on mapping and reprogramming the immune systemAditxt is actively adding distribution channel partners for AditxtScore(TM) throughout the U.S. and globallyThe company aims to expand reimbursement coverage for AditxtScore(TM) for COVID-19 from private insurance and public payers while developing and commercializing tests for other indicationsAditxt intends to advance its ADi(TM) therapeutics pipeline into clinical trials in the coming months,…

Continue Reading

Wednesday May 11, 2022 - 11:15 am

Silo Pharma Inc. (SILO) Spotlight: Ketamine

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or…

Continue Reading

Wednesday May 11, 2022 - 10:30 am

Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancerCNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier Berubicin dosing has begun in a potentially pivotal global trial that is recruiting glioblastoma multiforme…

Continue Reading

Friday May 06, 2022 - 9:00 am

Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial

Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”)MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwidePreclinical studies show CYB003 may have significant advantages over classic psilocybin In a significant step forward in the study of alternative treatments for major depressive disorder, Cybin (NEO:…

Continue Reading

Thursday Apr 28, 2022 - 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages

Earlier studies show that CYB004 via inhalation may solve existing challenges and support a clinical path forward for this important therapeuticCybin is currently developing CYB004 for the treatment of anxiety disordersThe new chemical entity is covered by a patent issued earlier this year Cybin (NEO: CYBN) (NYSE American: CYBN) has released data from a pharmacokinetic study focused on evaluating CYB004, the company’s proprietary deuterated dimethyltryptamine (“DMT”)…

Continue Reading

Monday Apr 18, 2022 - 9:30 am

Mullen Automotive Inc. (NASDAQ: MULN) Named EV Startup to ‘Watch Out For’ by Leading Auto Site

Mullen called “dark horse” in HotCars 2022 list of top EV startupsOther online articles also shining spotlight on what CarBuzz calls “the real deal” Mullen CEO calls FIVE model “just the start” Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is starting the new year with a bang: the company is ranked no. 2 on the HotCars 2022 list of top-10 EV startups (https://ibn.fm/Gb5IR).…

Continue Reading

Monday Apr 18, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO

World Intellectual Property Organization has published CYBN’s international patent applicationPublication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment optionsCompany continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled "Methods…

Continue Reading

Wednesday Apr 13, 2022 - 9:00 am

European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug

Novel brain cancer drug developer CNS Pharmaceuticals is developing a proprietary pharmaceutical candidate called Berubicin for the treatment of glioblastoma multiforme (“GBM”)CNS has received Fast Track designation for Berubicin, which will allow the company more frequent communications with the FDA CNS has initiated a global potentially pivotal clinical trial to evaluate Berubicin in treating GBM and began dosing patients at sites scattered across several states last…

Continue Reading

Tuesday Apr 12, 2022 - 9:15 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Gaining Advantage on Processing Rare Cannabinoids with the Help of Subsidiary Bay Medica

There is an urgent need for large-scale biosynthetic processing that preserves the purity and consistency of cannabinoidsAcquired by InMed in October 2021, Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sectorInMed has two cannabinol formulations currently in development for ocular and dermatological diseases – INM-088 (ocular for glaucoma) and INM-755 (dermatological cream…

Continue Reading

Tuesday Apr 12, 2022 - 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disordersIt also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolioFor 2022, the company plans to build on the progress achieved in 2021With new additions to its board, its conditional IRB approval, and the…

Continue Reading

Monday Apr 11, 2022 - 9:00 am

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine”Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeuticallySILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications “The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as…

Continue Reading

Monday Apr 11, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers

CNS Pharmaceuticals is a clinical stage biotechnology company focused on the development of novel treatments for brain tumorsThe company’s lead product candidate, Berubicin, is a novel anthracycline that is designed to cross the blood-brain barrierThe blood-brain barrier ordinarily hinders the vascular delivery of therapeutic substances to brain tumorsBy crossing this protective barrier, Berubicin holds promise for the thousands of adult Americans diagnosed with malignant central…

Continue Reading

Friday Apr 08, 2022 - 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

Recent study forecasts global mental health market to reach almost $538B by 2030One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and moreCybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated…

Continue Reading

Wednesday Apr 06, 2022 - 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Increasing Rare Cannabidiol Product Portfolio, Revenues

InMed Pharmaceuticals is a Canadian clinical-stage drug development company focused on the development of rare cannabinoids and their synthetic counterpoints for B2B sales and pharmaceutical potentialInMed expects to have rare cannabinoids CBDV and THCV available for B2B sale to the health and wellness market in the coming months, following on the heels of its CBC and CBT productsThe company recently reported its first revenues from…

Continue Reading

Tuesday Apr 05, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Recruitment for Study Measuring Ketamine’s Psychedelic Effect

Cybin-sponsored study will use Kernel Flow, Kernel’s quantitative neuroimaging.Company hopes to learn more about impact ketamine has on brain activity, overall mental well-being.Study results may lead to future studies supporting CYBN’s mission to develop psychedelics into therapeutics. Cybin’s (NEO: CYBN) (NYSE American: CYBN) efforts to transform the mental-health treatment landscape have reached a key milestone: the company is actively recruiting participants for its upcoming feasibility study…

Continue Reading

Tuesday Apr 05, 2022 - 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leveraging Growth Across Multiple Markets Including Mental Health, Healthcare IT

Mydecine was founded in 2020 as a response to the lack of innovation addressing mental health treatment and the therapeutic possibilities represented by psychedelic compounds and other novel moleculesThe world is experiencing a shortage of mental health resources, while faced with an increase in mental health issues on the heels of the pandemicMydecine is leveraging the psychedelic drugs market, the PTSD market, and healthcare IT…

Continue Reading

Monday Apr 04, 2022 - 9:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC

The three-day event showcased CNS through corporate presentation, fireside chat, and live question and answer sessions CNS has been granted both Orphan Drug Designation and Fast Track status from the FDA for Berubicin in 2020 and 2021, respectivelyCNS initiated a potentially pivotal global trial of Berubicin for recurrent Glioblastoma Multiforme (“GBM”) with the dosing of the first patients in the trial during 3Q 2021At the end…

Continue Reading

Thursday Mar 31, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reiterates Commitment to Operational Excellence, Advancing Berubicin Recognition

In a video message to shareholders, CEO John Climaco detailed the operational and clinical progress made by lead drug candidate Berubicin despite market volatility and share price fluctuationsCNS is currently enrolling patients into a potentially pivotal global drug trial of Berubicin for recurrent glioblastoma multiformeInterim analysis of the trial is currently expected as early as the first quarter of 2023, once 30-50% of trial patients…

Continue Reading

Tuesday Mar 29, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Update on Advances in Brain Cancer Drugs and Operational Financials

Texas-based CNS Pharmaceuticals is a novel brain cancer drug developer that is building a series of global clinical trials for its lead drug candidate, BerubicinCNS began dosing patients in a global trial last September to evaluate Berubicin in treating glioblastoma multiforme (“GBM”), currently an incurable brain cancerCNS received FDA Fast Track designation for Berubicin in June 2021 and FDA Orphan Drug designation for Berubicin in…

Continue Reading

Monday Mar 28, 2022 - 9:00 am

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addictionMydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing for its planned Phase 2 trialsThe company is targeting nicotine addiction…

Continue Reading

Thursday Mar 24, 2022 - 9:15 am

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Is a Leader in Psychedelic-Based Therapies; Recent Preclinical Research Shows Treatment Effective for MDD

Study shows that substantial antidepressant effects of psilocybin-based treatment, given with supportive psychotherapy, may last at least a year.Psilocybin could lead to significant, durable improvements in depression.Cybin is focused on improving overall mental health through psychedelic-based therapies. Johns Hopkins Medicine researchers have released a report noting that psilocybin treatment for major depression is effective for up to a year for many patients (https://ibn.fm/ZF8jH). That bodes…

Continue Reading

Thursday Mar 17, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows

More than 60% of American who suffer from mental health conditions want access to psychedelic optionsGrowing number of cities, states looking at decriminalizing use of psychedelic medicineCybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a…

Continue Reading

Thursday Mar 17, 2022 - 9:00 am

Metabolic Health Diseases Rising Globally, Nemaura Medical Inc. (NASDAQ: NMRD) Aims to Disrupt Market with Non-Invasive, Cost-Effective IoT Devices, Mikobo Coaching Program

Metabolic disease cases rising globally, diseases include diabetes, dementia, cardiovascular conditions, strokeCompanies in diagnostic space posting record revenues, double-digit YOY increasesNemaura Medical aims to disrupt the market with Mikobo program’s non-invasive sensor technology, companion mobile application and coaching programsCompetitor devices use microneedles coated with enzymes and polymers that can cause discomfort, trauma, and skin changes Clinical research reveals that volatile blood sugar fluctuations are a…

Continue Reading

Thursday Mar 03, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Company announced the first officially issued patentPatent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compoundsCYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office…

Continue Reading

Wednesday Mar 02, 2022 - 9:15 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) and BayMedica Rare Cannabinoids to Enter Market Q1 2022; Leveraging on Fast-Growing Global Health and Wellness Market

Over 140 rare cannabinoids exist in the cannabis plant – some with the potential to have more therapeutic benefits than those cannabinoids found prominently in the plantInMed and subsidiary BayMedica plan to release several rare cannabinoid products in the first half of 2022 Combination of complementary InMed and BayMedica business models key to increasing shareholders’ value  In 2020, the global health and wellness market reached $4.436…

Continue Reading

Wednesday Mar 02, 2022 - 9:00 am

Nemaura Medical Inc.’s (NASDAQ: NMRD) sugarBEAT(R) Wearable CGM Device Targets Billion-Dollar Global Diabetes Market

Global diabetes-related healthcare expenses are estimated at $966 billion in 2021A recent report reveals 537 million adults currently live with diabetes, projected to rise to 643 million by 2030 and 783 million by 2045 Glucose intake is an important factor in diabetes management, prevention and reversalNMRD’s sugarBEAT(R) wearable is a non-invasive, flexible CGM device helping diabetes and prediabetes patients monitor glucose levelsNMRD’s MiBoKo metabolic health program…

Continue Reading

Monday Feb 28, 2022 - 9:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Makes Exciting Drug Discovery for the Treatment of Mental health and Addiction Disorders – MYCO-005

Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compoundsMydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nauseaThe company is excited about this finding, terming it one of the many…

Continue Reading

Wednesday Feb 23, 2022 - 10:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics

Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSDThese results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizonMydecine is playing a vital role in pushing the knowledge of the benefits of psychedelic compounds by undertaking clinical research in partnership with academicsIn a recent interview, company…

Continue Reading

Tuesday Feb 22, 2022 - 9:30 am

AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) Is ‘One to Watch’

In the first quarter of 2022, AREV acquired Wright & Well Essentials Inc., a firm with an extensive hemp and cannabis line of branded products currently sold in Oregon and expanding markets.The company’s online sales and marketing platform, Medicine Merchant™, is in the final stages of development; the platform has the potential to revolutionize consumer access to therapeutic interventions and personalized medicine via partnerships with…

Continue Reading

Thursday Feb 17, 2022 - 1:12 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Seeks to Provide Non-Invasive Glucose Monitoring Solutions to Millions of Patients Worldwide

Over 420 million people around the globe currently have diabetes, with the figure set to rise by 55% over the next 25 yearsMillions of patients required to measure their blood glucose levels daily to accurately determine their insulin dosage amountsNemaura Medical has launched two constant glucose monitoring solutions – the SugarBEAT(R) device as well as the MiBoKo application, which seek to provide users with a…

Continue Reading

Tuesday Feb 15, 2022 - 9:30 am

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addictionMydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment optionsThe license allows Mydecine to provide psilocybin and MDMA…

Continue Reading

Monday Feb 14, 2022 - 9:30 am

Nemaura Medical Inc.’s (NASDAQ: NMRD) CEO Dr. Faz Chowdhury Addresses Growing CGM Demand at H.C. Wainwright BioConnect Conference

NMRD CEO Dr. Faz Chowdhury presented at H.C. Wainwright BioConnect Conference held January 10-13, 2022Presentation revealed growing need for CGM devices, diabetes market estimated at $150 billionNMRD's sugarBEAT(R) devices measure glucose at the skin surface, non-invasive, easy to useNMRD recently commenced product shipments in lieu of an order for 5,000 CGM devices and 200,000 sensors to UK licensing partner MySugarWatch LimitedNMRD recently announced launch of…

Continue Reading

Monday Feb 14, 2022 - 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study

Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technologyKernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experienceCYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward…

Continue Reading

Wednesday Feb 09, 2022 - 9:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Set to Capitalize on Glucose Monitoring Sector’s Exponential Growth Rate

The blood glucose monitoring system sector is expected to grow to a value of $27.2 billion by 2026, expanding at a CAGR of 9.6% between 2021-2026Over 420 million people around the globe currently have diabetes, with the American Diabetes Association recommending that all adults screen for the condition every three yearsNemaura Medical has sought to capitalize on the blood glucose monitoring sector’s phenomenal growth rate…

Continue Reading

Thursday Feb 03, 2022 - 10:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Strengthens Leading Role in Rare Cannabinoid Market Following New Product Launch, Key Acquisition

Cannabicitran is the first of four new rare cannabinoids InMed is planning to launch in the first half of the year to meet growing inbound demandThe launch demonstrates InMed’s ability to produce rare cannabinoids at scale, something only very few companies have achievedBayMedica acquisition, other key achievements in 2021, are positioning the company as a leading supplier of rare cannabinoids in the health and wellness…

Continue Reading

Wednesday Feb 02, 2022 - 12:38 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses

Canadian-based mental health treatment-focused biotechnology company Mydecine Innovations Group has been advancing research on the use and improvement of compounds found in nature, particularly the psychedelic psilocybin compoundMydecine recently announced an LOI with The Newly Institute to use Mydecine’s psilocybin and MDMA for treatment at The Newly’s mental health clinics nationwideThe LOI is the first collaboration under Mydecine’s SASSP program, which will provide psychedelic drug…

Continue Reading

Monday Jan 31, 2022 - 1:03 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year

Upcoming study supports CYBN’s mission to develop psychedelics into therapeutics.Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. Study may provide crucial “mind-imaging” information that has been previously missing. Cybin (NEO: CYBN) (NYSE American: CYBN) is starting off the new year right — the company has received approval from an Institutional Review Board (“IRB”) for a feasibility study using Kernel’s quantitative…

Continue Reading

Friday Jan 28, 2022 - 11:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Appoints Technical Healthcare Specialist Dr. Arash Ghadar as COO

NMRD appoints UK-based Dr. Arash Ghadar as Chief Operating Officer, brings decades of healthcare and technology experienceDr. Ghadar previously supervised product development lifecycles, feasibility studies, prototyping, validation, quality management, volume manufacturing, certificationNMRD commercializing sugarBEAT(R) non-invasive, flexible, CGM device, recently completed initial shipment to UK licensee MySugarWatch LimitedMySugarWatch Limited aims to market devices via subscription-based diabetes coaching and management service Nemaura Medical (NASDAQ: NMRD), a medical…

Continue Reading

Thursday Jan 27, 2022 - 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend

Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuseWell+Good says psychedelics “poised to change the course of mental health treatment”Cybin working to combine novel psychedelic molecules with controllable drug-delivery systems through proprietary deuterated process A USA Today article is touting psychedelics as the next big thing in mental health treatment (https://ibn.fm/3ZGGE). This forecast aligns perfectly with what Cybin (NEO: CYBN) (NYSE…

Continue Reading

Wednesday Jan 26, 2022 - 12:15 pm

InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging on the Growing Cannabinoid-Based Pharmaceuticals Market

The global cannabinoid-based pharmaceuticals market is projected to be valued at $50 billion by 2029InMed is leading the industry, laying down the foundation in manufacturing and clinical development of rare cannabinoidsIt is shedding light on the potential of rare cannabinoids and laying the groundwork on how to tap into the industry’s growth It is projected that by 2025, the global cannabis market will be valued…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).